Dr. Doug Warner joined eFFECTOR as Chief Medical Officer in 2022. Previously, Dr. Warner worked at Amgen where he held roles of increasing responsibility and oversaw extensive clinical development programs in multiple indications across oncology and general medicine. In his most recent position, Executive Medical Director, Group Product Area Lead, Dr. Warner provided development guidance and oversight over a broad portfolio of solid tumor immune-oncology and pathway inhibitor development programs that ranged from phase 1 to marketed products. Prior to this position, Dr. Warner was the Global Development Lead for several molecules including Vectibix®, XGEVA®, and Prolia®. In this role, Dr. Warner led evidence generation and oversaw the design, execution, and analysis of phase 1-3 clinical trials and post-marketing commitment studies. Throughout his tenure at Amgen, Dr. Warner worked closely with global regulatory agencies and was the clinical development leader for major regulatory filings worldwide.
Dr. Warner is co-author on numerous peer-reviewed articles including those in The Lancet, The Lancet Oncology, and The Journal of Clinical Oncology. He received his B.A. from the University of Pennsylvania, his M.D. from the Duke University School of Medicine, and his M.B.A. from the UCLA Anderson School of Management.